Literature DB >> 8627679

A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1.

O Yamada1, G Kraus, L Luznik, M Yu, F Wong-Staal.   

Abstract

We have previously shown that hairpin ribozymes targeting the human immunodeficiency virus (HIV) genome can effectively inhibit virus replication in a variety of primary and cultured hematopoietic cells. To further increase antiviral potency and minimize the chance of viral resistance, we have now cloned the stem-loop II sequences of the HIV type 1 Rev response element into ribozyme transcription cassettes. Fusion RNA molecules were shown to function both as RNA decoys and ribozymes. Stable Molt-4/8 cell lines expressing fusion RNA of stem-loop II and a ribozyme directed at the HIV-type 1 U5 sequence (MSLMJT) or its disabled counterpart (MSLdMJT) were generated. The expression of fusion RNA was persistent for at least 6 months without apparent cytotoxicity. When virus inhibition was examined after the cocultivation of transduced cells with chronically infected Jurkat cells, much greater protection was observed in MSLMJT cells than in MSLdMJT or MMJT (expressing only the ribozyme) cells. Furthermore, to specifically compare the ribozyme activities in various transduced cells, we determined the quantitative levels of proviral DNA in the first round of virus replication (7 h after infection with HXB2). By competitive PCR, the proviral DNA levels in MSLMJT and MMJT cells were found to be reduced to 1/7 and 1/3, respectively, compared with those in MSLdMJT and MdMJT cells. These results suggest not only that the greater inhibition afforded by this fusion RNA was due to its function both as decoy and ribozyme but also that the ribozyme activity may be facilitated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627679      PMCID: PMC189982     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells.

Authors:  C Y Ou; S Kwok; S W Mitchell; D H Mack; J J Sninsky; J W Krebs; P Feorino; D Warfield; G Schochetman
Journal:  Science       Date:  1988-01-15       Impact factor: 47.728

2.  rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA.

Authors:  B K Felber; M Hadzopoulou-Cladaras; C Cladaras; T Copeland; G N Pavlakis
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

3.  The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA.

Authors:  M H Malim; J Hauber; S Y Le; J V Maizel; B R Cullen
Journal:  Nature       Date:  1989-03-16       Impact factor: 49.962

4.  HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA.

Authors:  M B Feinberg; R F Jarrett; A Aldovini; R C Gallo; F Wong-Staal
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

5.  In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1.

Authors:  M Yu; E Poeschla; O Yamada; P Degrandis; M C Leavitt; M Heusch; J K Yees; F Wong-Staal; A Hampel
Journal:  Virology       Date:  1995-01-10       Impact factor: 3.616

6.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

7.  Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells.

Authors:  O Yamada; G Kraus; M C Leavitt; M Yu; F Wong-Staal
Journal:  Virology       Date:  1994-11-15       Impact factor: 3.616

8.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

9.  Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes.

Authors:  M C Leavitt; M Yu; O Yamada; G Kraus; D Looney; E Poeschla; F Wong-Staal
Journal:  Hum Gene Ther       Date:  1994-09       Impact factor: 5.695

10.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

View more
  14 in total

1.  Inhibition of hepatitis B virus X gene expression by novel DNA enzymes.

Authors:  R Goila; A C Banerjea
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

2.  Polyvalent Rev decoys act as artificial Rev-responsive elements.

Authors:  T L Symensma; S Baskerville; A Yan; A D Ellington
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences.

Authors:  Gunter Kraus; Rebeca Geffin; Gina Spruill; Andrea K Young; Rachel Seivright; Diana Cardona; Jennifer Burzawa; H James Hnatyszyn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 4.  RNA-mediated virus resistance in transgenic plants.

Authors:  M Prins; R Goldbach
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

Review 5.  Antiviral ribozymes. New jobs for ancient molecules.

Authors:  A Menke; G Hobom
Journal:  Mol Biotechnol       Date:  1997-08       Impact factor: 2.695

6.  Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes.

Authors:  L M Alvarez-Salas; A E Cullinan; A Siwkowski; A Hampel; J A DiPaolo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

7.  A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml.

Authors:  M L Collins; B Irvine; D Tyner; E Fine; C Zayati; C Chang; T Horn; D Ahle; J Detmer; L P Shen; J Kolberg; S Bushnell; M S Urdea; D D Ho
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

8.  Inhibition of transcription by the TAR RNA of HIV-1 in a nuclear extract of HeLa cells.

Authors:  R Yamamoto; S Koseki; J Ohkawa; K Murakami; S Nishikawa; K Taira; P K Kumar
Journal:  Nucleic Acids Res       Date:  1997-09-01       Impact factor: 16.971

9.  Gene therapy for HIV infections: Intracellular immunization.

Authors:  A Piché
Journal:  Can J Infect Dis       Date:  1999-07

10.  Dose-response resistance to HIV-1/MuLV pseudotype virus ex vivo in a hairpin ribozyme transgenic mouse model.

Authors:  M Andäng; J Hinkula; G Hotchkiss; S Larsson; S Britton; F Wong-Staal; B Wahren; L Ahrlund-Richter
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.